irinotecan has been researched along with Proteinuria in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H | 1 |
| Banerjee, A; Boyett, JM; Fangusaro, J; Fouladi, M; Friedman, HS; Gajjar, A; Gilbertson, RJ; Goldman, S; Gururangan, S; Jakacki, R; Kun, LE; McLendon, RE; Onar-Thomas, A; Packer, RJ; Pollack, IF; Poussaint, TY; Warren, KE; Wu, S | 1 |
| Chohnabayashi, N; Ishikawa, G; Jinta, T; Kitamura, A; Mochizuki, S; Nishimura, N; Suzuki, K; Tomishima, Y; Yamano, Y | 1 |
| Ameratunga, MS; Grant, R; Khasraw, M; Pavlakis, N; Wheeler, H | 1 |
| Huang, YT; Liao, WJ; Luo, W; Ma, L; Shi, M; Wang, XN; Wen, Q | 1 |
| Frese, S; Frese-Schaper, M; Gugger, M; Monestier, M; Zbaeren, J | 1 |
| Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S | 1 |
2 review(s) available for irinotecan and Proteinuria
| Article | Year |
|---|---|
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Progression-Free Survival; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2018 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2014 |
2 trial(s) available for irinotecan and Proteinuria
| Article | Year |
|---|---|
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Fatigue; Hemorrhage; Humans; Hypertension; Infant; Injections, Intravenous; Irinotecan; Neoplasm Recurrence, Local; Proteinuria; Young Adult | 2013 |
Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Complementarity Determining Regions; Female; Fluorouracil; Genes, T-Cell Receptor beta; Hematuria; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Proteinuria; Receptors, Antigen, T-Cell; T-Lymphocyte Subsets; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
3 other study(ies) available for irinotecan and Proteinuria
| Article | Year |
|---|---|
Long-term survival of a patient with extensive small cell carcinoma of unknown primary etiology complicated by nephrotic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Edema; Etoposide; Glomerulonephritis, Membranous; Humans; Irinotecan; Lymphatic Metastasis; Neoplasms, Unknown Primary; Nephrotic Syndrome; Paraneoplastic Syndromes; Pleural Effusion, Malignant; Proteinuria; Radiotherapy, Adjuvant; Remission Induction; Tomography, X-Ray Computed | 2014 |
Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.
Topics: Animals; Autoimmune Diseases; Camptothecin; Crosses, Genetic; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Irinotecan; Lupus Nephritis; Mice; Mice, Inbred NZB; Proteinuria; Random Allocation; Survival Analysis; Time Factors; Topoisomerase I Inhibitors | 2010 |
Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Epistaxis; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Hypertension; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Proteinuria; Retrospective Studies; Tegafur; Thrombosis; Treatment Outcome | 2011 |